Recently, a phase I clinical trial evaluated its safety and efficacy in combination with low-intensity chemotherapy and navitoclax (a dual BCL2/Bcl-xl inhibitor) in R/R B/T-ALL and lymphoblastic lymphoma. The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.